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Long-term glycemic control and the rate of progression of early diabetic
kidney disease. In this prospective study of 11.9 years duration (range 9
to 14), we examined the progression of albuminuria prior to and after
the onset of microalbuminuria [albumin excretion rate (AER): 20 to 200
pg/minute]. Glycated hemoglobin (HbA1), AER and blood pressure
were measured every six months. Twenty-two (13 type I, 9 type II)
patients were identified in whom AER increased progressively (progres-
sors). These patients were compared with 22 others matched for age,
duration and type of diabetes in whom AER did not change significantly
during the study period (non-progressors). In the progressors, the rate
of increase in AER correlated with mean HbAI for the study period in
patients with type I (r = 0.68, P < 0.01) and type II diabetes (r = 0.71,
P < 0.05). Furthermore, AER began increasing well before the conven-
tional 20 pg/minute threshold of microalbuminuria had been reached
and within the first five years of diagnosis of type I diabetes. We
conclude that in predisposed diabetic patients, long-term gIycemic
control is correlated with the rate of development of early renal
abnormalities. Repeated measurements of AER from the time of
diagnosis may be useful in the early detection of patients who will
develop microalbuminuria and ultimately overt diabetic nephropathy.
The natural history of diabetic nephropathy is incompletely
understood. Clinical nephropathy develops in approximately 30
to 40% of patients with type I diabetes [1, 2] and in a lesser
proportion of those with type II diabetes [3]. Several prospec-
tive studies have demonstrated that microalbuminuria [albumin
excretion rate (AER): 20 to 200 pg/minute] predicts subsequent
nephropathy in type I diabetes [4, 5] and clinical proteinuria and
cardiovascular death in type II diabetes [6, 7]. Indeed, the
presence of microalbuminuria may indicate early renal disease
rather than simply being a risk factor for its subsequent devel-
opment [8]. However, few studies have examined the natural
history of diabetic nephropathy from an early stage at which
some reversibility of the disease process may be possible [9].
The importance of microalbuminuria in the evolution of
diabetic renal disease is well-established [5, 7]; however, the
transition from normoalbuminuria to microalbuminuria remains
poorly defined. For instance, although it is known that persis-
tent microalbuminuria is not usually found within five years of
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diagnosis of type I diabetes [10], the pattern by which AER
begins to increase in these patients has not been studied.
Furthermore, the relationship between long-term glycemic con-
trol and the rate of progression of AER early in the evolution of
diabetic kidney disease is unclear. This study was undertaken,
firstly, to examine the relationship between long-term glycemic
control and the evolution of early diabetic kidney disease.
Secondly, the study sought to establish the pattern of progres-
sion from normo- to microalbuminuria by multiple within indi-
vidual measurements in order to detect patients at risk of renal
disease before the conventional 20 pg/mm threshold is reached
[11, 12]. If this were achieved it may allow earlier intervention
before irreversible renal damage occurs.
Methods
Patients
From 1978, patients of the Austin Hospital diabetes clinic
were recruited into a study of evolving diabetic nephropathy.
Serial measurements of urinary albumin excretion, plasma
creatinine, blood pressure and glycated hemoglobin were per-
formed. Data on all diabetic patients studied between 1978 and
1992 were evaluated. Of 478 patients, 98 were identified in
whom there were at least nine years of longitudinal data. Of
these 98 patients, 18 were excluded from further analysis
because of overt nephropathy or the possibility that significant
albuminuria may be due to causes other than diabetic renal
disease. These causes included: cardiac failure, recurrent uri-
nary tract infections, non-diabetic renal disease and macroal-
buminuria (AER > 200 mg/mm) at entry. Of the 80 remaining
patients, we identified 22 patients (progressors) who developed
persistent microalbuminuria (AER: 20 to 200 g/min in 3 of 4
consecutive specimens, adapted from [13]) during the study
period and whose AER progressed as defined by a statistically
significant increase in log10 AER (Table 1). From the 53 patients
who did not progress, 22 patients (non-progressors) matcled for
age, duration and type of diabetes served as controls. This was
necessary as comparisons between the 22 progressors and all 53
non-progressors would have been confounded by the difference
in duration of diabetes [8.0 1.8 vs. 4.6 0.1 years (mean
sEM), P < 0.01, respectively]. Patients were designated as
having type I diabetes if they had persistent ketonuria, weight
loss on presentation and insulin dependency within one month
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Table 1. Characteristics of progressors
Rate of
Age at Duration of Duration of change
Patient entry diabetes at Diabetes follow-up in AER
number years entry years type years %/year r
1 44 7 1 13 12.8 0.45"
2 40 0 I 13 49.2 0.67"'
3 14 0 I 9 10.3 Ø44a
4 32 0 1 14 17.0 0.75c
5 30 0 I 9 45•9 Q•79C
6 9 1 I 14 20.7 0.73c
7 65 22 I 9 30.5 0.71c
8 46 7 1 9 125.1 0.96c
9 46 33 I 12 22.4 O.67c
10 24 5 I 14 53.5 0.98c
11 45 8 I 14 21.4 Ø73C
12 47 12 1 14 26.2 0.66c
13 40 15 I 12 53.7 0.92c
14 60 7 II 9 53.6 0.93c
15 68 14 II 11 38.8 0.74c
16 56 4 II 14 49.0 0.91c
17 52 0 II 12 18.2 0.70c
18 57 8 II 12 68.3 0.93c
19 42 15 II 11 36.7 0.85c
20 63 13 II 14 16.6 0.57a
21 60 3 II 12 51.3 0.81c
22 50 2 II 11 42.3 0.70c
r = correlation co-efficient for rate of change of AER vs. time.
ap< 0.05
bp <0.001
' P < 0.0001
of diagnosis. All other patients were classified as having type II
diabetes.
Clinical examination
Patients were examined every six months in the clinic. Blood
pressure was measured in the supine position after five minutes
of recumbency, by a physician using the disappearance of the
Korotkoff sounds (phase V) to determine diastolic pressure.
Patients whose blood pressure was >160/95 mm Hg on at least
three occasions were commenced on antihypertensive treat-
ment. Sixteen progressors received antihypertensive treatment
during the study period.
Laboratory techniques
All investigations were performed every six months, and
these included: plasma creatinine, fasting plasma glucose, gly-
cated hemoglobin (HbA,), midstream urine microscopy and
culture and 24 hour urine collection for albumin. Plasma creat-
mine was assayed by autoanalyzer (Beckman Astra 8, Palo
Alto, California, USA). HbA, (nondiabetic range: 5 to 7.5%)
was measured by the thiobarbituric acid technique [14] from
1978 to 1981 and after 1981 by column chromatography pre-
ceded by a dialysis step [15]. There was a close correlation
between the two methods (r = 0.90, N = 35, P < 0.001), and a
conversion formulawas derived so that results could be pooled
for statistical analysis [16]. Urinary albumin was measured by a
co4ted tube radioimmunoassay technique with an interassay
coefficient of variation of 10.9% [17]. Clinical and laboratory
data obtained during periods of acute metabolic decompensa-
tion, such as ketoacidosis, during pregnancy, or while receiving
treatment for urinary tract infection, were excluded from anal-
ysis.
Statistics
Data were analyzed using two-tailed parametric methods
including linear regression analysis and paired and unpaired
Student's t-tests. Because of a positively skewed distribution,
AER was logarithmically transformed before statistical analysis
and expressed as a geometric mean and tolerance factor. In
order to investigate the relationship between log10 AER and
time, linear regression analysis was performed.
The annual percentage increase in AER was calculated as
(antilog a — 1) X 100, where a is the slope of the regression line
[18]. All analyses were performed using the Statview SE +
Graphics package (Abacus Concepts, Berkeley, California,
USA) on an Apple Macintosh IIcx computer (Apple Computer




In the progressors, eight patients (6 type I, 2 type II)
progressed from normoalbuminuria to microalbuminuria, nine
patients (5 type I, 4 type II) progressed from microalbuminuria
to macroalbuminuria and five patients (2 type I, 3 type II)
progressed from normoalbuminuria through microalbuminuria
to macroalbuminuria.
By the end of the study period, AER had increased from
13.5 x/÷ 1.4 sg/min (geometric mean x/÷ tolerance factor) to
189 x/÷ 1.6 tg/min in the progressors with type I diabetes and
from 16.1 x/÷ 1.4 to 342 x/÷ 1.6 in progressors with type II
diabetes. Rates of increase in AER were similar in patients with
type I and type II diabetes, being 38 8%/year (mean SEM)
in patients with type I diabetes and 42 6%/year in patients
with type II diabetes (Table 1). AER commenced increasing
from the time of entry in each subject, including those 13
patients in whom the initial AER was well below the microal-
buminuric range. This can be seen in a representative patient in
whom AER progressed from normo- to micro- and then to
macroalbuminuria (Fig. 1). Furthermore, AER commenced
rising from entry in four type I diabetic patients followed from
diagnosis.
Pro gressors versus non-pro gressors
There were no significant differences between progressors
and non-progressors with either type I or type II diabetes with
regard to mean HbA1, the number of samples collected during
the study period or blood pressure at entry (Tables 2 and 3). The
lack of difference in long-term glycernic control between pro-
gressors and non-progressors was maintained when all 53
non-progressors were evaluated (type I, HbA1 10.6 0.4%
vs. 10.2 0.2%; type II, 10.5 0.7% vs. 9.6 0.4%, mean
SEM, progressors vs. non-progressors). Furthermore, there was
no significant difference between the progressors and all 53
non-progressors with regard to initial systolic and diastolic
blood pressure, sex ratio and diabetes type.





Fig. 1. Change in AER in a patient with type II diabetes who
progresses from normoalbuminuria through microalbuminuria to mac-
roalbuminuria during 14 years of follow-up. Shaded area denotes
microalbuminuric range of 20 to 200 jrglmin.
Glycemic control
In the progressors, there was a significant correlation be-
tween the rate of increase in AER and the mean HbA1 for the
study period in both type I (r= 0.68, P < 0.01) (Fig. 2) and type
II diabetic patients (r = 0.71, P < 0.05; Fig. 3), but not with age,
duration of diabetes or mean blood pressure.
Blood pressure
In the progressors with type I diabetes, both systolic and
diastolic blood pressure increased during the study period
(Table 3). No change in blood pressure was found in non-
progressors with type I diabetes. In patients with type II
diabetes, systolic blood pressure increased during the study
period in both progressors and non-progressors (Table 3). By
the end of the study period, progressors with type I diabetes
had higher systolic and diastolic blood pressure than non-
progressors with type I diabetes, but no difference was detected
in blood pressure between progressors and non-progressors
with type II diabetes. Similarly, with regard to antihypertensive
therapy, more progressors than non-progressors with type I
diabetes were receiving treatment (Table 2). In patients with
type II diabetes this trend did not reach statistical significance.
In individual progressors no relationship between initial blood
pressure and the rate of increase in AER was observed.
Discussion
In the present study, the principal findings are that the rate of
increase in AER is related to the degree of long-term glycemic
control and that patients at risk of nephropathy may be identi-
fied by serial measurements of AER from diagnosis before they
reach the 20 jgImin threshold for microalbuminuria.
Although the relationship between glycemic control and
diabetic nephropathy has been the subject of much research
[19—24], no previously published study has prospectively exam-
ined the influence of glycemic control on the progression of
early diabetic renal disease by repeated measurements of gly-
cated hemoglobin and AER over such a long period. Our data
suggest that in individuals with diabetes who are predisposed to
the development of nephropathy, there is an association be-
tween long-term glycemic control and the rate at which the
nephropathic process evolves. In such individuals, possible
mechanisms of glucose mediated injury may include nonenzy-
matic glycation, activation of the poiyol pathway, glucose
auto-oxidation and activation of protein kinase C and phospho-
lipase A2 [25]. The finding that metabolic control was not
significantly different between progressors and non-progressors
suggests that while hyperglycemia is a necessary prerequisite it
is not sufficient to explain susceptibility to diabetic nephropa-
thy. This is consistent with recent studies which implicate
genetic factors [26] such as a predisposition to hypertension [27,
28] or decreased heparan sulphate proteoglycan synthesis [29]
in the development of diabetic nephropathy. The importance of
glycemic control in determining the progression of nephropathy
appears to be influenced by the stage of the disease. For
instance, patients with overt proteinuria do not derive benefit
from improved glycemic control [301. However, in patients with
microalbuminuria, improved glycemic control diminishes the
rate of AER progression and possibly delays the transition to
overt nephropathy [23, 24].
The current approach to detect early diabetic kidney disease
is by the identification of microalbuminüria [12]. The present
study suggests that at risk patients may be identified before they
reach the 20 gImin threshold by serial measurements of AER
from diagnosis, since AER begins to rise exponentially in
progressors well before the development of microalbuminuria.
This was also fOund in newly diagnosed type I diabetic patients
in whom AER began to rise following diagnosis, even though
microalbuminuria is not usually seen within the first five years
of type I diabetes [31]. Although the commencement of a
progressive rise in albuminuria at diagnosis in type I diabetes
has been previously suggested from extrapolation of data from
short-term studies [32], it has not been previously established
by prospective study. This early rise in AER may explain why
patients who develop microalbuminuria over a five year period
have higher AER at baseline than those patients who remain
normoalbuminuric [33]. Similar results have been reported by
Chase and colleagues [34] who found that patients with border-
line elevations of AER were more likely to progress to microal-
buminuria during a five year period than were patients with
AER < 7.6 g/min, the 95th percentile for nondiabetic subjects.
These studies suggest that repeated measurements of AER may
allow earlier detection and possibly treatment of those patients
who will progress to overt renal disease than does the 20 g/min
threshold. In type II diabetic patients, the exponential rise in
AER among progressors was similar to that in patients with
type I diabetes. However, in type II diabetes diagnosis may
follow many years of hyperglycemia, and the relationship
between microalbuminuria and evolving renal disease is less
well-defined [35].
Arterial hypertension accelerates ti1 "?1ution of established
diabetic nephropathy, while antihypertensive therapy reduces
AER and the rate of decline in GFR [36, 371. In this study,
patients with hypertension were treated with antihypertensive
therapy. Despite this, blood pressure was still higher in pro-
gressors with type I diabetes when compared with non-progres-
sors. Furthermore, there was a trend for more progressors than
non-progressors to be receiving antihypertensive therapy.
.S
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Table 2. Clinical data in diabetic patients with and without progressive albuminuria
Type I Type II
Non-progressors Progressors Non-progressors Progressors
N 13 13 9 9
Gender: male, female 8, 5 12, 1 5, 4 8, 1
Age at entry years 36.3 4.1 37.1 4.2 54.2 2.4 56,4 2.6
Duration at entry years 7 2.9 8.4 2.8 5.6 1.5 7.3 1.9
Follow-up years 12.7 0.7 12.5 0.9 11.6 0.8 12.1 0.7
Number of samples 28 4 26. 4 24 3 25 4
Hypertensivea, normotensive 4 9 9, 4c 3, 6 7, 2
Mean HbAI, %b 10.1 0.3 10.6 0.4 9.5 0.5 10.5 0.7
Data are presented as mean SaM.
a Receiving antihypertensive treatment at end of study period.b Mean HbAJ for the entire study period.
P < 0.05: progressors versus non-progressors.
Table 3. Blood pressure at the beginning and end of the study
Type I Type II
Non-progressors Progressors Non-progressors Progressors
Initial Final Initial Final Initial Final Initial Final
Systolic BP, mm Hga 127 6 136 4 127 5 150 6b,c 134 5 152 3C 139 6 163 5c
Diastolic BP, mm Hga 80 3 79 2 78 3 87 2b,c 82 3 84 3 87 3 85 3
a Data.are mean SEM.b P < 0.05, progressors versus non-progressors at end of Study,


































Fig. 2. Relation between the rate of change in AER and mean HbA, in
13 type 1 diabetic patients with progressive albuminuria. The rate of
change in AER was significantly correlated with mean HbA1 (r = 0.68,
P < 0.01).
We conclude that the rate of progression of albuminuria in
diabetic patients who develop persistent microalbuminuria was
correlated with the degree of long-term glycemic control. This
implies that patients with early diabetic kidney disease may
benefit from optimization of the level of glycemia. The finding
of a progressive increase in AER, prior to the 20 p.glmin









Fig. 3. Relationship between the rate of change in AER and mean
HbA, in 9 type II diabetic patients with progressive albuminuria. The
rate of change in AER was significantly correlated with mean HbAI
(r = 0.71, P <0.05).
repeated measurements of AER from the time of diagnosis may
be useful. in the early identification of patients who will ulti-
mately develop diabetic nephropathy and may allow interven-
tion at a potentially reversible stage of the disease process.
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